Diagnostic Consultative Centre Ascendent EOOD — Clinical Trial Site

41 Registered trials

14 Currently recruiting

Organisation

Diagnostic Consultative Centre Ascendent EOOD

Location

Sofia, Bulgaria

Identifier

ORG-100039746

Address

Ulitsa Bacho Kiro 47, 1202, Bulgaria

Departments

-
#2202
#9002
10030
2003
7515: NA
Bed space for short term stay
Bed Space for Short-term Stay
BG014
Cabinet 10
Cardiology Cabinet
Cardiology Consulting Room
Dermatology
Dermatovenerology
Diagnostic and Consultancy Center
Diagnostic-Consultative Centre Ascendent - clinical trial rooms
Ear, Nose, Throat
Endocrinology and Metabolic Diseases Consulting Room
N/A
NA
Not applicable

Clinical trials at this site (41)

Search interface

HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted

2025-521503-43-00 Atopic dermatitis 4 2026-02-12
A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended

2024-516240-26-00 Influenza 5 2024-10-11
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
Conducting a quality study of the medicinal product - Vortioxetine Ended

2023-509946-36-00 No therapeutic indication in the current trial with hea 2 2024-06-29
A study to investigate the effect on lung function of an approved COPD treatment (BGF, with HFA propellant) compared to BGF formulated with… Ended

2023-506565-57-00 Moderate to Severe Chronic Obstructive Pulmonary Diseas 5 2024-06-21
A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended

2022-501310-57-00 Endometriosis related pain 4 2024-02-05
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended

2023-503576-25-00 Severe Hypertriglyceridemia 5 2023-09-22
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis Ended

2024-513591-18-00 Postmenopausal osteoporosis 5 2023-04-26
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended

2024-511263-28-00 Hypercholesterolemia 6 2022-04-08
A study to investigate the similarity of two different Tiotropium inhalers in healthy volunteers. Ended

2023-509025-41-00 No therapeutic indication in the current trial with hea 2
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and… Ended

2024-512417-41-00 Osteoporosis 5
A study to investigate the similarity of two different Tiotropium inhalers in healthy volunteers. Ended

2024-515876-10-00 No therapeutic indication in the present bioequivalence 2